Omeros 将来の成長
Future 基準チェック /56
Omerosは、32.8%と41.1%でそれぞれ年率32.8%で利益と収益が成長すると予測される一方、EPSはgrowで36.1%年率。
主要情報
32.8%
収益成長率
36.08%
EPS成長率
| Pharmaceuticals 収益成長 | 11.9% |
| 収益成長率 | 41.1% |
| 将来の株主資本利益率 | n/a |
| アナリストカバレッジ | Low |
| 最終更新日 | 15 May 2026 |
今後の成長に関する最新情報
Recent updates
新しいナラティブ • Mar 05
Complement Platform And Novo Nordisk Deal Will Reshape Long Term Outlook
Catalysts About Omeros Omeros is a biopharmaceutical company focused on complement biology, oncology and other high unmet medical needs through antibody, small molecule and biologic platforms. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Dec 24
Omeros: Stock Pops On Yartemlea Approval, Longer-Term Upside Likely
Summary Omeros (OMER) receives FDA approval for Yartemlea (narsoplimab) in TA-TMA, driving shares up nearly 80% to a $1bn+ valuation. Yartemlea is the first and only approved therapy for TA-TMA, showing high complete response rates and strong survival benefits in pivotal trials. I estimate Yartemlea's peak revenue potential at ~$300m, with commercialization pacing dependent on awareness, funding, and OMER's ability to scale. I reiterate a Buy rating, expecting OMER's valuation to exceed $1.5bn by end-2026, supported by Yartemlea and the Novo Nordisk milestone pipeline. Read the full article on Seeking AlphaSeeking Alpha • Feb 24
Omeros Corporation: Scientifically Compelling Again, But The Delay Has Cost Us
Summary Omeros Corporation's stock rebounded after successful data analysis for narsoplimab, showing 68% lower death risk in HSCT-TMA patients compared to historical controls. FDA requested new statistical analysis for narsoplimab's BLA resubmission, which proved successful, leading to a potential approval by late 2025. Financial risks include limited cash runway and potential market constraints due to upcoming generic competition and insurance issues. Despite scientific promise, I recommend caution for OMER stock due to financial instability and market uncertainties; monitoring the situation closely is advised. Read the full article on Seeking AlphaSeeking Alpha • Nov 17
Omeros Q3 2024 - Updates On OMIDRIA And Narsoplimab Lead To Liquidity Concerns
Summary Evaluates Omeros' Q3 2024 performance, referencing the earnings call, 10-Q, and earnings press release. Assesses financial metrics and operational highlights from Q3 2024 to determine the company's health. Reviews strategic initiatives and future growth prospects based on recent earnings. Awards a rating of "Hold" based on financial performance and strategic outlook. Read the full article on Seeking AlphaSeeking Alpha • Jul 19
Omeros: Troubled Company Working Its Way Out Of The Morass
Summary During its annual meeting, Omeros described its recent financial moves to extend its debt maturities. Narsoplimab, OMER's lead therapy, has struggled to advance past late-stage trials. With its lead asset stuck in an FDA approval thicket, the Company is a high-risk investment. Read the full article on Seeking AlphaSeeking Alpha • Feb 14
Omeros: Still Worth A Look Despite Narsoplimab Woes
Summary Omeros has suffered from underperformance of its Narsoplimab lead therapy. OMIDRIA, Omeros' sole approved therapy, has provided significant cash infusions as Omeros has sold it off piecemeal. Well situated for liquidity over the next two years, Omeros will need to raise significant funds thereafter. Read the full article on Seeking Alpha分析記事 • Jul 26
Is Omeros (NASDAQ:OMER) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Mar 17
Omeros (NASDAQ:OMER) Is Making Moderate Use Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Oct 05
Omeros: Taking It To The Max
Summary Omeros stock has been drifting with a downward bias since it reported its Q4 2021 earnings. Its problem stems from its protracted delay in getting FDA approval of its narsoplimab in treatment of HSCT-TMA. Omeros' recent deal works to maintain its liquidity without shareholder dilution.Seeking Alpha • Sep 15
Omeros falls 11% after reporting clinical data for COVID-19 therapy
The shares of commercial-stage biopharma, Omeros Corporation (NASDAQ:OMER) fell ~11% in the morning hours Thursday after the company reported data from a clinical trial involving critically ill COVID-19 patients who received its experimental therapy narsoplimab in addition to standard of care. The I-SPY COVID Trial, sponsored by Quantum Leap Healthcare Collaborative was designed to measure the time to recovery the risk of mortality in critically ill COVID patients as primary endpoints. The investigators of I-SPY randomized 91 to the narsoplimab arm and 116 to the control arm. All patients had received standard of care including dexamethasone and remdesivir. The addition of narsoplimab cut the mortality risk (hazard ratio [HR]=0.81, with probability [HR <1] equal to 0.77) and its experimental therapy was linked to the biggest drop in mortality risk among all drugs tested in the trial so far, OMER said. However, the trial did not indicate that narsoplimab dropped the time to recovery.Seeking Alpha • Aug 16
Omeros: Managing An Investment After A Winning Trade
Omeros has had it rough over the last two years after the FDA delayed narsoplimab’s PDUFA and eventually sent a CRL. OMER plummeted from around $20 per share to $2. The market sell-off put OMER under additional selling pressure and moved the ticker into the oversold territory. I took advantage of the oversold and undervalued opportunity. OMER rocketed through my sell targets leaving me with a “house money” position. Now I have to determine how I am going to manage my OMER position. I discuss my plans for my "house money" OMER position. Omeros (OMER) had a rough go over the last two years after the FDA accepted the company’s BLA filing for narsoplimab for HSCT-TMA back in January of last year. The FDA set narsoplimab’s PDUFA for October of 2021, but the FDA delayed the PDUFA… and ultimately issued a CRL. As a result, OMER's share price plummeted from around $20 per share to $2 per share in roughly 16 months. Meanwhile, I was waiting for an opportunity to establish a speculative position in OMER for a profitable trade, but the negative headlines prevented me from pulling the trigger. So, OMER remained a "Bio Boom" candidate for my Seeking Alpha Marketplace Service, Compounding Healthcare. Then, the market decided to sell off for six months and put small-cap healthcare tickers under pressure, which pushed OMER into the oversold territory and de-risked the investment. Using my valuation models and some technical analysis, I determined OMER was worthy of speculative investment at around $3.50 per share and would be undervalued at $1.88 per share. Those targets were hit and I am now celebrating a successful trade after OMER rocketed through my sell targets leaving me with a “house money” position. Now, I must determine what I am going to do with these remaining shares after a fruitful multi-bagger trade. Has OMER’s long-term outlook improved? What is the Bull Thesis? Should I look to book additional profits? Should look to reload if the share price drops back to my buy targets? First, I will discuss why I started a position in OMER, and why decided to go “house money”. Furthermore, I intend to ascertain the company’s current status and long-term outlook to determine if I should. In addition, I will discuss some of the risks as well as my current plan for my OMER position going forward. Max Doom Into Bio Boom As I mentioned in my introduction, Omeros experienced a tough losing streak regarding narsoplimab’s BLA for HSCT-TMA. The PDUFA delay and the subsequent CRL crumpled OMER’s share price… then, the market sell-off melted OMER down to under $2 per share. At that time, OMER was trading at a market cap of less than $150M, which is about the amount of cash on hand. OMER Daily Chart (Trendspider) OMER Daily Chart Enhanced View (Trendspider) This extreme level of selling provided an opportunity to take advantage of the discounted valuation with the potential of a mean reversion trade. It is important to note, that narsoplimab is in multiple late-stage clinical trials and still may possibly be approved for HSCT-TMA. Indeed, it is reasonable to see a solid sell-off following a CRL but to cut the ticker’s share price by 90% when the company still has multiple balls still left in play made OMER a prime candidate for the Compounding Healthcare’ Bio Boom Portfolio. The Compounding Healthcare Bio Boom candidates must be able to provide a near-term trade opportunity with a superior risk-reward profile. This unlocks the ability to quickly book some profits and de-risk the investment to hold for a long-term investment prospect. OMER presented the opportunity to buy the ticker in an oversold condition and at a discounted valuation. Yet, the company’s long-term bull thesis appeared to be intact. Essentially, OMER was a near-perfect Bio Boom candidate under $2 per share. Thankfully, OMER acted like a Bio Boom ticker and was able was snapback off the 52-week lows and blasted through my Sell Target 1 and Sell Target 2 to transition into a “house money” status. Now, my original investment value has been removed from the market, thus, de-risking my remaining shares to allow Omeros time to execute on their objectives. Developing A Long-Term Outlook For me, OMER was an ideal Bio Boom ticker because it presented a great trade opportunity that had long-term prospects, but we will need another level of sophistication to determine if OMER will stay in the Bio Boom Portfolio, or will the ticker be mothballed until it provides another opportunity. Essentially, is OMER worthy of a long-term investment? In order for the ticker to remain in the Bio Boom Portfolio, it either has to offer multi-bagger upside potential, or the ticker has to be a great trading vessel that can generate several trades over the course of about five years. For Omeros, I would point to the numerous catalysts that could trigger some trading prospects, while also unlocking some pending intrinsic value. Most of these catalysts come from the company’s flagship candidate, narsoplimab, their leading MASP-2 inhibitor candidate for TA-TMA, IgA Nephropathy, aHUS, Lupus Nephritis & Other Renal Diseases, and even COVID-19. Narsoplimab Pipeline Programs (Omeros) The stem cell transplant-associated thrombotic microangiopathy “TA-TMA” indication was CRL’d by the FDA. However, the company is not giving up on this indication and had a Type A post-action meeting with the FDA in the first quarter. Following the meeting, the company decided to file a dispute resolution request in June, which will permit the company to appeal the decision made to the Office of New Drugs “OND”. The company has met with the OND and they are now currently awaiting a decision, which the company expects this month (August). Obviously, approval would have a dramatic impact on the company’s outlook and should bolster the share price. Moreover, narsoplimab has the potential to treat acute severe COVID-19 as well as for long COVID. The company believes that the lectin pathway is a point of attack in both acute COVID and long COVID. Despite our progress in the COVID-19 vaccine and therapeutics, people are still dying from COVID-19 and millions of people are still dealing with long COVID. Therefore, there is still a huge demand for COVID-19 therapeutics. The company is also evaluating narsoplimab for the treatment of IgA nephropathy, which is in a Phase III study and has a scheduled read-out by the middle of next year. In addition to narsoplimab, Omeros has several other pipeline assets that could be supplementary value drivers in the future. The company’s second MASP-2 program, OMS1029, is a long-acting second-gen MASP-2 antibody that is in Phase I clinical trials. The company expects OMS1029 to be “complementary to narsoplimab”. Omeros is also working on small molecule MASP-2 inhibitors as well as oral MASP-2 inhibitors. OMS906 is the company’s MASP-3 inhibitor for Paroxysmal Nocturnal Hemoglobinuria “PNH”. OMS906 has the FDA’s orphan drug designation for PNH. The company expects to present Phase I trial results at a major Congress later this year. Moreover, the company is looking to evaluate OMS906 against C3 glomerulopathy. The company also has OMS527, their PDE7 inhibitor asset for addictive disorders. The company is looking for “third-party funding to continue development.” Emory University testing PDE7 inhibitors to improve L-DOPA-induced dyskinesias and should see the dyskinesia data early next year. Obviously, having a product that could work for addictive disorders as well as Parkinson’s would be a valuable asset with blockbuster potential. Into the bargain, the company made a deal with Rayner Surgical for the ophthalmic drug, OMIDRIA. This was a “strategic divestiture” that included an upfront payment of $125M with an extra $200M in commercial milestone payments along with royalties on net sales of OMIDRIA. Altogether, Omeros stated that “the transaction is valued in excess of $1 billion.” Considering the points above, I would Omeros has plenty of potential catalysts and drivers that could dramatically change the company’s long-term outlook. My long-term thesis will center on OMIDRIA providing Omeros with significant cash flow from royalties to help offset expenses until they can get narsoplimab across the finish line. Then they can turn their focus to developing their MASP-2, and MASP-3 inhibitor franchise and become a leader in the alternative complement pathway. So, there is some justification for holding some OMER shares beyond a simple mean reversion trade. Downside Risks On the other hand, Omeros has a few downside risks that investors need to consider when managing their position. Firstly, the company needs to get narsoplimab through the FDA in at least one indication. Obviously, approval of the TA-TMA indication would be ideal and could improve the sentiment around the rest of narsoplimab’s programs. However, it is possible that OND’s decision does not favor Omeros, and the company is stuck running another clinical trial or possibly abandoning the indication. Clearly, that would have a negative impact on the drug’s prospects and hurt the company’s near-term outlook.Seeking Alpha • Jul 28
Omeros granted FDA’s Orphan Drug designation for PNH candidate
The U.S. Food and Drug Administration (FDA) has awarded its Orphan Drug designation to commercial-stage biopharma Omeros Corporation (NASDAQ:OMER) for a candidate targeted at paroxysmal nocturnal hemoglobinuria (PNH) on Thursday, according to a federal registry. According to the FDA, the experimental therapy is identified as “humanized immunoglobulin G4 monoclonal antibody directed against mannan-binding lectin-associated serine protease-3 (MASP-3)” in generic terms. PNH is an acquired blood disorder that leads to the premature breakdown of red blood cells, causing conditions such as anemia and hemoglobinuria. In addition to tax credits for clinical trial costs and waiver of the user fee for marketing applications, the developers of orphan drugs can claim seven years of marketing exclusivity upon regulatory approval of the treatment. Omeros (OMER) plans to start a Phase 1b clinical trial for its MASP-3 inhibitor OMS906 in PNH.Seeking Alpha • Jul 04
Omeros: Follow The Bouncing Ball
Omeros has undergone a savage price discovery process yielding a possible near-term bottom The annual shareholder meeting provided encouraging support for Omeros bulls. Omeros is a compelling buy for experienced investors who have an appetite for high-risk biotech. This article provides an update to my most recent Omeros (OMER) article, "Omeros: On Death's Door" ("Death's Door"). Management has recently issued a comprehensive report during its annual shareholders meeting on 06/17/2022 ("Annual Meeting") providing important new insights on Omeros' value to shareholders. Omeros' shares have been cursed and blessed with extreme volatility in a down market. The last year and a half have been profoundly eventful for Omeros. The FDA accepted its narsoplimab BLA in treatment of HSCT-TMA for filing in 01/2021. Its PDUFA date was set for 10/2021. Everything seemed all set up. Then the FDA delayed the PDUFA; then to investors' and management's horror and surprise, it ultimately issued a CRL. The PDUFA delay and the subsequent CRL poleaxed Omeros' share price. Shares dropped from the high teens in 05/2021 down to $13-$16 range on the PDUFA delay; later following the CRL, they dropped to single digits. As the situation has played out, Omeros shares are continuing to drop. They traded ~$7 for several months; then they dropped to successively lower levels. They hit something of a bottom in mid 06/2022, trading below $2.00 on light volume during several sessions. At these lows it was trading at a market cap of <$150 million right around the sum of its cash on hand. The market finally seemed to wake to its foolishness. Shares quickly recovered, rising to close at $4.64 as I write on 07/01/2022. Tomfoolery, from its low of $1.86 Omeros' bump to $4.64 reflects an increase of 164%, in a period of two weeks! Omeros' tremulous trading over the last year+ is shown by the price and market cap chart below: Data by YCharts I have searched for an explanation. The one that comes most readily to mind is that the lows reflect the FDA news exacerbated by general market doldrums. These doldrums have been particularly pronounced for small loss-generating biotechs like Omeros. The recent updrafts reflect short covering as Omeros' towering short interest of >20% gets riled by the prospects of a colossal squeeze. On the other hand, there may be big news afoot as suggested by the following 07/01/2022 comment to Death's Door: Seeking Alpha As an Omeros bull and as shareholder, I am hopeful that a deal is in the works. During the Annual Meeting CEO Demopulos assured shareholders that Omeros was open to deal making as exemplified by the Rayner deal. The Annual Meeting provided extra data points for evaluating Omeros' future prospects. It was a sad day in Omeros-land when the FDA issued its CRL; instead of celebrating a big win, shareholders were relegated to trying to read the tea leaves on Omeros' Type A meeting with the FDA. Ultimately the situation deteriorated to the point that Omeros threw up its hands. It decided that its only viable path forward was to resort to the FDA's dispute resolution process. During the Annual Meeting, Omeros issued the following presentation slide advising on the status of the regulatory process and its path forward: Omeros Annual Shareholders' Meeting (central.virtualshareholdermeeting.com) CEO Demopulos provided further color on the status. He confirmed that Omeros was currently appealing the FDA's decision to the FDA's Office of New Drugs [OND]. It submitted its briefing package requesting formal resolution earlier in June. Omeros expects a meeting with OND in early July. FDA rules would then dictate a decision in early August. He characterized Omeros and its advisors as convinced that their position was "very strong" and that approval of narsoplimab was warranted. He did not speculate as to what the actual FDA response to the dispute resolution was likely to be. As discussed in Death's Door, he had previously indicated that actual reversals were not the norm; rather a more likely outcome would be for the parties to work out a middle ground. Luckily for antsy shareholders, the resolution should take form without delay, in early August. Omeros presents an attractive, albeit highly speculative, value proposition. Omeros shares are searching for a price point. The only thing which seems assured is that buying interest perks up when the shares drop below $2.00, or below a market cap of ~$150 million. As matters now (07/02/2022) stand Omeros has significant assets consistent with a market cap many multiples higher than its current ~$0.166 billion. If approved, narsoplimab in treatment of HSCT alone presents blockbuster potential.Seeking Alpha • Jun 02
Omeros: On Death's Door
Omeros shareholders have watched with dismay as its share price languishes ever lower. Omeros' $200 million OMIDRIA milestone is cloaked in uncertainty. Omeros' decision to battle the FDA over its narsoplimab in treatment of HSCT-TMA is a good call, however, it speaks to rough times for shareholders. Omeros should survive and may yet thrive.Seeking Alpha • May 03
Omeros: The Weight Of The Wait, A Conundrum
Omeros' OMIDRIA sale has substantially improved its financial prospects. Omeros' CRL gangplank is agonizing for shareholders as they wait for FDA response to its type A meeting. Omeros' growing short interest and its sinking share price will likely continue until it provides positive feedback on its FDA interactions.Seeking Alpha • Feb 21
Omeros: Despite Its Promise, The CRL Is A Huge Obstacle
Omeros was handed a CRL for narsoplimab. The lack of clarity surrounding the CRL is disconcerting. I will stay on the sidelines despite the seemingly attractive price.Seeking Alpha • Dec 06
Omeros: A New Year Beckons
Omeros' 2021 was a year to forget with the stock dropping during the year all the way from >$23 to below $6.00. Omeros' 2022 gives it a shot to redux its narsoplimab in treatment of HSCT-TMA. Omeros' 2022 will also be the year to provide new clarity on OMIDRIA's role in light of major new deal.分析記事 • Dec 04
Some Analysts Just Cut Their Omeros Corporation (NASDAQ:OMER) Estimates
Today is shaping up negative for Omeros Corporation ( NASDAQ:OMER ) shareholders, with the analysts delivering a...Seeking Alpha • Oct 15
Omeros: What's Left
Halloween goblins came early for Omeros shareholders with its 10/2021 "deficiency" announcement. Omeros' financial condition is fraught with daunting prospects of near-term dilution. Omeros' pipeline is front and center for the near future, with OMIDRIA playing a critical role.Seeking Alpha • Sep 14
Omeros: The Prize Is Nigh (Again)
Omeros' rescheduled PDUFA is upcoming on 10/17/2021. Its chances for gain in case of favorable FDA decision present a compelling risk-reward scenario for shareholders. OMIDRIA is back in growth mode but has yet to prove a sustainable level of revenues.Seeking Alpha • Jul 03
Omeros: PDUFA Delay Presents An Opportunity
Omeros has had its PDUFA delayed by three months. The reason is that the FDA needs additional time to review data it had asked for. This represents a buying opportunity.業績と収益の成長予測
| 日付 | 収益 | 収益 | フリー・キャッシュフロー | 営業活動によるキャッシュ | 平均アナリスト数 |
|---|---|---|---|---|---|
| 12/31/2028 | 565 | 404 | 118 | 190 | 3 |
| 12/31/2027 | 199 | 81 | -52 | 21 | 4 |
| 3/31/2026 | 10 | 84 | 145 | -95 | N/A |
| 12/31/2025 | N/A | -5 | 124 | -116 | N/A |
| 9/30/2025 | N/A | -121 | -105 | -105 | N/A |
| 6/30/2025 | N/A | -137 | -119 | -119 | N/A |
| 3/31/2025 | N/A | -176 | -143 | -143 | N/A |
| 12/31/2024 | N/A | -183 | -149 | -149 | N/A |
| 9/30/2024 | N/A | -185 | -155 | -155 | N/A |
| 6/30/2024 | N/A | -200 | -156 | -155 | N/A |
| 3/31/2024 | N/A | -179 | -142 | -142 | N/A |
| 12/31/2023 | N/A | -175 | 74 | 75 | N/A |
| 9/30/2023 | N/A | -182 | 84 | 84 | N/A |
| 6/30/2023 | N/A | -185 | 90 | 90 | N/A |
| 3/31/2023 | N/A | -182 | 103 | 103 | N/A |
| 12/31/2022 | N/A | -182 | -87 | -86 | N/A |
| 9/30/2022 | N/A | -183 | -79 | -79 | N/A |
| 6/30/2022 | N/A | -173 | -77 | -77 | N/A |
| 3/31/2022 | N/A | -181 | -85 | -85 | N/A |
| 12/31/2021 | N/A | -192 | -110 | -110 | N/A |
| 9/30/2021 | -63 | -217 | -110 | -110 | N/A |
| 6/30/2021 | -37 | -211 | -121 | -121 | N/A |
| 3/31/2021 | -24 | -194 | -131 | -131 | N/A |
| 12/31/2020 | N/A | -173 | -100 | -100 | N/A |
| 9/30/2020 | 97 | -130 | -105 | -105 | N/A |
| 6/30/2020 | 100 | -108 | -78 | -77 | N/A |
| 3/31/2020 | 114 | -89 | -56 | -56 | N/A |
| 12/31/2019 | N/A | -147 | N/A | -60 | N/A |
| 9/30/2019 | 100 | -79 | N/A | -62 | N/A |
| 6/30/2019 | 75 | -102 | N/A | -91 | N/A |
| 3/31/2019 | 50 | -121 | N/A | -105 | N/A |
| 12/31/2018 | 30 | -127 | N/A | -104 | N/A |
| 9/30/2018 | 22 | -120 | N/A | -83 | N/A |
| 6/30/2018 | 39 | -88 | N/A | -58 | N/A |
| 3/31/2018 | 54 | -68 | N/A | -35 | N/A |
| 12/31/2017 | 65 | -53 | N/A | -36 | N/A |
| 9/30/2017 | 64 | -57 | N/A | -43 | N/A |
| 6/30/2017 | 54 | -63 | N/A | -43 | N/A |
| 3/31/2017 | 46 | -61 | N/A | -48 | N/A |
| 12/31/2016 | 42 | -67 | N/A | -52 | N/A |
| 9/30/2016 | 35 | -67 | N/A | -57 | N/A |
| 6/30/2016 | 27 | -73 | N/A | -61 | N/A |
| 3/31/2016 | 21 | -77 | N/A | -64 | N/A |
| 12/31/2015 | 14 | -75 | N/A | -65 | N/A |
| 9/30/2015 | 7 | -76 | N/A | -64 | N/A |
| 6/30/2015 | 4 | -74 | N/A | -66 | N/A |
アナリストによる今後の成長予測
収入対貯蓄率: OMERの予測収益成長率 (年間32.8% ) は 貯蓄率 ( 3.5% ) を上回っています。
収益対市場: OMERの収益 ( 32.8% ) はUS市場 ( 16.8% ) よりも速いペースで成長すると予測されています。
高成長収益: OMERの収益は今後 3 年間で 大幅に 増加すると予想されています。
収益対市場: OMERの収益 ( 41.1% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。
高い収益成長: OMERの収益 ( 41.1% ) 20%よりも速いペースで成長すると予測されています。
一株当たり利益成長率予想
将来の株主資本利益率
将来のROE: OMERの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です
成長企業の発掘
企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/15 15:14 |
| 終値 | 2026/05/15 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Omeros Corporation 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Gregory Harrison | BofA Global Research |
| Ritu Baral | Canaccord Genuity |
| Elemer Piros | Cantor Fitzgerald & Co. |